Latest News

Non-Small Cell Lung Cancer - Immunotherapy

Corticosteroid Link To NSCLC Immunotherapy Response Challenged

  • 25 Jun 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

US researchers dispute the hypothesis that use of corticosteroids may hamper non-small-cell lung cancer response to immunotherapy...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Corticosteroid Link To NSCLC Immunotherapy Response Challenged

Breast Cancer - Ovarian Cancer - Clinical Research - Anticancer Agents - Immunotherapy

Niraparib Plus Pembrolizumab ‘Promising’ For Advanced TNBC, Ovarian Cancer

  • 20 Jun 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Patients with advanced triple-negative breast cancer and recurrent ovarian cancer have responded to treatment with the PARP inhibitor niraparib given alongside the PD-1 inhibitor pembrolizumab...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Niraparib Plus Pembrolizumab ‘Promising’ For Advanced TNBC, Ovarian Cancer

Non-Small Cell Lung Cancer - Anticancer Agents

Gefitinib–Chemotherapy Boosts Advanced EGFR-Mutated NSCLC Survival

  • 10 Jun 2019

Combining first-line gefitinib with pemetrexed and carboplatin significantly improves the outcome of advanced non-small-cell lung cancer patients with an activating EGFR mutation...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Gefitinib–Chemotherapy Boosts Advanced EGFR-Mutated NSCLC Survival

Breast Cancer - Anticancer Agents

MONALEESA-7: Ribociclib Delivers OS Benefit For Premenopausal Advanced Breast Cancer

  • 07 Jun 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Premenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer derive a significant overall survival benefit from the addition of ribociclib to endocrine therapy...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof MONALEESA-7: Ribociclib Delivers OS Benefit For Premenopausal Advanced Breast Cancer

Head and Neck Cancers - Anticancer Agents - Radiation Oncology

Induction Chemotherapy Boosts Nasopharyngeal Carcinoma Response

  • 03 Jun 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Use of induction chemotherapy significantly improves survival for patients undergoing chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Induction Chemotherapy Boosts Nasopharyngeal Carcinoma Response

Prostate Cancer - Anticancer Agents

Darolutamide QoL Benefit Demonstrated For Nonmetastatic CRPC

  • 01 Jun 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Results from the ARAMIS trial of men with castration-resistant prostate cancer indicate darolutamide fends off pain progression and quality of life deterioration, as well as metastases, compared with placebo...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Darolutamide QoL Benefit Demonstrated For Nonmetastatic CRPC

Pancreatic Cancer - Anticancer Agents - Radiation Oncology

Total Neoadjuvant Approach Downstages Locally Advanced Pancreatic Cancer

  • 31 May 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Giving FOLFIRINOX, losartan and chemoradiotherapy before surgery may help achieve margin-negative resection in patients with locally advanced pancreatic adenocarcinoma...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Total Neoadjuvant Approach Downstages Locally Advanced Pancreatic Cancer

Small Cell Lung Cancer - Personalised/Precision Medicine - Immunotherapy

EGFR Mutation Allele Influences NSCLC Immune Checkpoint Inhibitor Response

  • 17 May 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Assessing EGFR mutation alterations could help predict non-small-cell lung cancer response to immune checkpoint blockade...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof EGFR Mutation Allele Influences NSCLC Immune Checkpoint Inhibitor Response

Breast Cancer - Therapy - Anticancer Agents

GeparSepto Update Confirms Neoadjuvant NAB-Paclitaxel Benefit For Early Breast Cancer

  • 16 May 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Disease-free survival is extended with use of NAB-paclitaxel compared with the solvent-based formulation for women who require chemotherapy before breast cancer surgery...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof GeparSepto Update Confirms Neoadjuvant NAB-Paclitaxel Benefit For Early Breast Cancer

Urothelial Cancers - Ovarian Cancer - Immunotherapy

KEYNOTE Results Show Pembrolizumab Activity For Advanced Urothelial, Ovarian Cancers

  • 09 May 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Updated KEYNOTE-045 findings confirm pembrolizumab overall survival benefit for platinum-refractory urothelial cancer, while KEYNOTE-100 indicates the PD-1 inhibitor has modest activity against recurrent ovarian cancer...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof KEYNOTE Results Show Pembrolizumab Activity For Advanced Urothelial, Ovarian Cancers

Breast Cancer - Clinical Research - Anticancer Agents

Tucidinostat–Exemestane May Boost Advanced HR-Positive/HER2-Negative Breast Cancer Survival

  • 03 May 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Combining exemestane with a subtype-selective histone deacetylase inhibitor may improve progression-free survival in postmenopausal women with advanced HR-positive, HER2-negative breast cancer...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Tucidinostat–Exemestane May Boost Advanced HR-Positive/HER2-Negative Breast Cancer Survival

Breast Cancer - Prostate Cancer - Thoracic Malignancies - Translational Research - Complications/Toxicities of Treatment - Radiation Oncology

Radiation Sensitivity Biomarkers Demonstrated

  • 02 May 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

A lymphocyte assay measuring apoptosis could help identify cancer patients with increased sensitivity to radiation...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Radiation Sensitivity Biomarkers Demonstrated

Gynaecological Malignancies

ESMO–ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease

Published in 2019 – Ann Oncol (2019); 00: 1–34 
Authors: N. Colombo, C. Sessa, A. du Bois, J. Ledermann, W. G. McCluggage, I. McNeish, P. Morice, S. Pignata, I. Ray-Coquard, I. Vergote, T. Baert, I. Belaroussi, A. Dashora, S. Olbrecht, F. Planchamp & D. Querleu

view detailsof ESMO–ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease

Ovarian Cancer - Anticancer Agents

QUADRA Demonstrates Late-Line Ovarian Cancer Benefit With Niraparib

  • 08 Apr 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Heavily pretreated ovarian cancer patients may experience a survival benefit from niraparib...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof QUADRA Demonstrates Late-Line Ovarian Cancer Benefit With Niraparib

Thoracic Malignancies - Mesothelioma - Clinical Research - Immunotherapy

CAR T-Cell Therapy Shows Potential Against Malignant Pleural Disease

  • 03 Apr 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Early results suggest CAR T-cell therapy may be feasible for patients with mesothelin-expressing thoracic tumours...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof CAR T-Cell Therapy Shows Potential Against Malignant Pleural Disease